La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cannara Biotech Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Zohar Krivorot

Directeur général

CA$300.0k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	5.6yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.7yrs
Durée moyenne du mandat des membres du conseil d'administration	5.3yrs

Mises à jour récentes de la gestion

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Aug 22

Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Aug 21

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Jul 14

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

Analyse de la rémunération des PDG

Comment la rémunération de Zohar Krivorot a-t-elle évolué par rapport aux bénéfices de Cannara Biotech?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
May 31 2024	n/a	n/a	CA$5m
Feb 29 2024	n/a	n/a	CA$6m
Nov 30 2023	n/a	n/a	CA$9m
Aug 31 2023	CA$300k	CA$300k	CA$7m
May 31 2023	n/a	n/a	CA$5m
Feb 28 2023	n/a	n/a	CA$3m
Nov 30 2022	n/a	n/a	CA$3m
Aug 31 2022	CA$75k	CA$75k	CA$2m
May 31 2022	n/a	n/a	CA$884k
Feb 28 2022	n/a	n/a	CA$1m
Nov 30 2021	n/a	n/a	CA$1m
Aug 31 2021	n/a	n/a	-CA$2m
May 31 2021	n/a	n/a	-CA$7m
Feb 28 2021	n/a	n/a	-CA$11m
Nov 30 2020	n/a	n/a	-CA$13m
Aug 31 2020	CA$92k	CA$92k	-CA$12m
May 31 2020	n/a	n/a	-CA$12m
Feb 29 2020	n/a	n/a	-CA$12m
Nov 30 2019	n/a	n/a	-CA$13m
Aug 31 2019	CA$150k	CA$150k	-CA$12m

Rémunération vs marché: La rémunération totale de Zohar ($USD 220.00K ) est dans la moyenne des entreprises de taille similaire sur le marché Canadian ($USD 176.00K ).

Rémunération et revenus: La rémunération de Zohar a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Zohar Krivorot (47 yo)

5.6yrs

Titularisation

CA$300,000

Compensation

Mr. Zohar Krivorot serves as Chief Executive Officer of Cannara Biotech Inc. since 2019, Director since December 31, 2018 and is its Founder, Chairman of the Board. He served as President at Cannara Biotec...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Zohar Krivorot	CEO & Chairman	5.6yrs	CA$300.00k	pas de données
Nicholas Sosiak	Chief Financial Officer	3.8yrs	CA$240.00k	0.031% CA$ 21.5k
Avi Krivorot	Chief Technology Officer	no data	CA$300.00k	0.052% CA$ 36.4k
Anthony Manouk	VP of Compliance & GM	no data	CA$160.00k	0.0049% CA$ 3.4k
Brian Sherman	General Counsel & VP Legal Affairs	no data	pas de données	0.019% CA$ 12.9k
David Abitbol	Vice President of Marketing	3.6yrs	pas de données	pas de données
Scott Carroll	Vice President of Marketing & Sales	no data	pas de données	0.0034% CA$ 2.4k
France Landry	Vice President of Human Resources	1.8yrs	pas de données	pas de données
Julia Bouvet	Chief of Staff	no data	pas de données	pas de données
Etienne Ledoux	Executive Officer	no data	CA$300.00k	pas de données

3.7yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de LOVE est considérée comme expérimentée (ancienneté moyenne 3.7 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Zohar Krivorot	CEO & Chairman	5.7yrs	CA$300.00k	pas de données
Jacob Kay	Independent Director	5.3yrs	CA$20.00k	0.24% CA$ 168.6k
Donald Olds	Independent Lead Director	3.8yrs	CA$32.50k	1.34% CA$ 932.2k
Derek Stern	Independent Director	5.7yrs	pas de données	0.42% CA$ 289.5k
Mary Durocher	Independent Director	4.3yrs	CA$17.50k	pas de données

5.3yrs

Durée moyenne de l'emploi

60.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de LOVE sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

Cannara Biotech Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Independent Director recently bought CA$60k worth of stock

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Independent Director recently bought CA$81k worth of stock

Recent updates

Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023)

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen